Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
公司代码CSTL
公司名称Castle Biosciences Inc
上市日期Jul 25, 2019
CEOMaetzold (Derek J)
员工数量761
证券类型Ordinary Share
年结日Jul 25
公司地址505 S Friendswood Drive
城市FRIENDSWOOD
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编77546
电话18667889007
网址https://castlebiosciences.com/
公司代码CSTL
上市日期Jul 25, 2019
CEOMaetzold (Derek J)